Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • behavior (3)
  • control group (1)
  • dropouts (1)
  • humans (1)
  • men (3)
  • opioid receptor (1)
  • sexual (1)
  • sexual behavior (10)
  • vertigo (1)
  • Sizes of these terms reflect their relevance to your search.

    Compulsive sexual behavior disorder (CSBD) is a common disorder affecting different areas of life, although studies focusing on pharmacological treatment are sparse. To investigate whether the opioid receptor antagonist naltrexone is feasible and tolerable and can provide symptom reduction in CSBD. Twenty men aged 27-60 years (mean = 38.8 years, standard deviation = 10.3) with CSBD seeking treatment in an outpatient nonforensic clinic received four weeks of naltrexone 25-50 mg. Measurements were made before, during, and four weeks after treatment. The self-assessment Hypersexual Disorder: Current Assessment Scale (HD: CAS) score was the primary outcome measure, and secondary outcomes were the Hypersexual Behavior Inventory (HBI) score, reported adverse effects, adherence to treatment, and dropouts. There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone. Even though some of the effects remained after treatment, the increased scores on HD: CAS indicated worsening of CSBD symptoms. The most reported side effects were fatigue (55%), nausea (30%), vertigo (30%), and abdominal pain (30%). However, there were no serious adverse effects leading to discontinuation of naltrexone. Despite side effects being common, naltrexone seems to be feasible in the treatment of CSBD. Being the first nonforensic prospective trial on naltrexone in CSBD, this study provides novel insights on a pharmacological intervention. However, owing to the small sample size and the lack of a control group, conclusions of effectiveness should be interpreted with caution. Naltrexone is feasible and tolerable and may reduce symptoms of CSBD; nevertheless, future studies should ensure a randomized controlled procedure to evaluate possible effectiveness. Savard J, Öberg KG, Chatzittofis A, et al. Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men. J Sex Med 2020;17:1544-1552. Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.


    Josephine Savard, Katarina Görts Öberg, Andreas Chatzittofis, Cecilia Dhejne, Stefan Arver, Jussi Jokinen. Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men. The journal of sexual medicine. 2020 Aug;17(8):1544-1552

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32532705

    View Full Text